



Vasostri[®] (vasopressin) – First-time generic

- On January 5, 2022, [Eagle Pharmaceuticals announced](#) the launch of an [AP-rated](#) generic version of Par Pharmaceutical's [Vasostri[®] \(vasopressin\)](#) injection on January 17, 2022.
 - Eagle Pharmaceuticals has been granted [180-days of marketing exclusivity](#) for generic Vasostri[®].
- Vasostri[®] is approved to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
- Annual U.S. sales for Vasostri[®] totaled \$890 million for the month ended September 30, 2021.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.